Phase I Study to Determine the Safety and Efficacy of a PIKA Rabies Vaccine Containing the PIKA Adjuvant

Trial Profile

Phase I Study to Determine the Safety and Efficacy of a PIKA Rabies Vaccine Containing the PIKA Adjuvant

Completed
Phase of Trial: Phase I

Latest Information Update: 12 Jan 2017

At a glance

  • Drugs Rabies vaccine Yisheng Biopharma (Primary)
  • Indications Rabies
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Yisheng Biopharma
  • Most Recent Events

    • 12 Jan 2017 Primary endpoint (Titer level of Rabies Virus Neutralizing Antibody (RVNA) from serum at day 14 and 42 after the first injection) has been met.
    • 12 Jan 2017 Results published in the Vaccine
    • 14 Jan 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top